In vivo retargeting of adenovirus type 5 to ?v?6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery

• Main Authors: Coughlan, Lynda (Author), Vallath, Sabari (Author), Saha, Antonio (Author), Flak, Magdalena (Author), MacNeish, Ian A. (Author), Vassaux, Georges (Author), Marshall, John F. (Author), Hart, Ian R. (Author), Thomas, Gareth J. (Author)
• Format: Article
• Language: English
• Published: 2009-07.
• Subjects: Article
• Online Access: Get fulltext

 A key impediment to successful cancer therapy with adenoviral vectors is the inefficient transduction of malignant tissue in vivo. Compounding this problem is the lack of cancer-specific targets, coupled with a shortage of corresponding high-efficiency ligands, permitting selective retargeting. The epithelial cell-specific integrin ?v?6 represents an attractive target for directed therapy since it is generally not expressed on normal epithelium but is upregulated in numerous carcinomas, where it plays a role in tumor progression. We previously have characterized a high-affinity, ?v?6-selective peptide (A20FMDV2) derived from VP1 of foot-and-mouth disease virus. We generated recombinant adenovirus type 5 (Ad5) fiber knob, incorporating A20FMDV2 in the HI loop, for which we validated the selectivity of binding and functional inhibition of ?v?6. The corresponding ?v?6-retargeted virus Ad5-EGFPA20 exhibited up to 50-fold increases in coxsackievirus- and-adenovirus-receptor-independent transduction and up to 480-fold-increased cytotoxicity on a panel of ?v?6-positive human carcinoma lines compared with Ad5-EGFPWT. Using an ?v?6-positive (DX3-?6) xenograft model, we observed a ~2-fold enhancement in tumor uptake over Ad5-EGFPWT following systemic delivery. Furthermore, ~5-fold-fewer Ad5-EGFPA20 genomes were detected in the liver (P = 0.0002), correlating with reduced serum transaminase levels and E1A expression. Warfarin pretreatment, to deplete coagulation factors, did not improve tumor uptake significantly with either virus but did significantly reduce liver sequestration and hepatic toxicity. The ability of Ad5-EGFPA20 to improve delivery to ?v?6, combined with its reduced hepatic tropism and toxicity, highlights its potential as a prototype virus for future clinical investigation.